NCT04354090View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

December 27, 2018

Study Completion Date

June 22, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

JY09

Subcutaneous injection

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Beijing Dongfang Biotech Co., Ltd.

INDUSTRY

NCT04354090 - Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09 | Biotech Hunter | Biotech Hunter